SABCS 2022 Conference Coverage


 

SABCS 2022 Long-Term Survival of the GeparOLA Study: Neoadjuvant Paclitaxel/Olaparib vs. Paclitaxel/Carboplatinum in Patients With HER2- BC and Homologous Recombination Deficiency

102 views
January 20, 2023
Comments 0
Login to view comments. Click here to Login